+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atopic Dermatitis Drugs Market Research Report by Route of Administration (Injectable ROA, Oral ROA, and Tropical ROA), Drug Class, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4904629
  • Report
  • April 2022
  • Region: Global
  • 218 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • AbbVie Inc.
  • Biofrontera AG
  • Eli Lilly and Company
  • Fujisawa Healthcare
  • GlaxoSmithKline PLC
  • LEO Pharma A/S
The Global Atopic Dermatitis Drugs Market size was estimated at USD 7,059.49 million in 2021, USD 7,523.08 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.74% to reach USD 10,443.19 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Atopic Dermatitis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Route of Administration, the market was studied across Injectable ROA, Oral ROA, and Tropical ROA.
  • Based on Drug Class, the market was studied across Biologics, Calcineurin Inhibitors, Corticosteroids, and PDE4 Inhibitors.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Atopic Dermatitis Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Atopic Dermatitis Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Atopic Dermatitis Drugs Market, including AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Connectics Corporation, Eli Lilly and Company, Encore Dermatology, Inc, Fujisawa Healthcare, Galderma S.A., GlaxoSmithKline PLC, Hoffmann-La Roche AG, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Atopic Dermatitis Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Atopic Dermatitis Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Atopic Dermatitis Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Atopic Dermatitis Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Atopic Dermatitis Drugs Market?
6. What is the market share of the leading vendors in the Global Atopic Dermatitis Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Atopic Dermatitis Drugs Market?
Frequently Asked Questions about the Global Atopic Dermatitis Drugs Market

What is the estimated value of the Global Atopic Dermatitis Drugs Market?

The Global Atopic Dermatitis Drugs Market was estimated to be valued at $7059.5 Million in 2021.

What is the growth rate of the Global Atopic Dermatitis Drugs Market?

The growth rate of the Global Atopic Dermatitis Drugs Market is 6.7%, with an estimated value of $10443.2 Million by 2027.

What is the forecasted size of the Global Atopic Dermatitis Drugs Market?

The Global Atopic Dermatitis Drugs Market is estimated to be worth $10443.2 Million by 2027.

Who are the key companies in the Global Atopic Dermatitis Drugs Market?

Key companies in the Global Atopic Dermatitis Drugs Market include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol, Myers Squibb Company, Connectics Corporation, Eli Lilly and Company and Fujisawa Healthcare.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Biofrontera AG
  • Eli Lilly and Company
  • Fujisawa Healthcare
  • GlaxoSmithKline PLC
  • LEO Pharma A/S

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of atopic dermatitis
5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
5.1.2. Restraints
5.1.2.1. High cost of therapeutics
5.1.3. Opportunities
5.1.3.1. Rising awareness regarding the availability of treatments for the disease
5.1.3.2. Growing access to treatment in various developing countries
5.1.4. Challenges
5.1.4.1. Adverse effects associated with the use of medication
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Atopic Dermatitis Drugs Market, by Route of Administration
6.1. Introduction
6.2. Injectable ROA
6.3. Oral ROA
6.4. Tropical ROA
7. Atopic Dermatitis Drugs Market, by Drug Class
7.1. Introduction
7.2. Biologics
7.3. Calcineurin Inhibitors
7.4. Corticosteroids
7.5. PDE4 Inhibitors
8. Americas Atopic Dermatitis Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Atopic Dermatitis Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Atopic Dermatitis Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. AbbVie Inc.
12.2. Bausch Health Companies Inc.
12.3. Bayer AG
12.4. Biofrontera AG
12.5. Bristol-Myers Squibb Company
12.6. Connectics Corporation
12.7. Eli Lilly and Company
12.8. Encore Dermatology, Inc
12.9. Fujisawa Healthcare
12.10. Galderma S.A.
12.11. GlaxoSmithKline PLC
12.12. Hoffmann-La Roche AG
12.13. LEO Pharma A/S
12.14. Meda AB
12.15. Mylan N.V.
12.16. Novartis AG
12.17. Pfizer Inc.
12.18. Regeneron Pharmaceuticals, Inc
12.19. Sanofi S.A.
12.20. Teva Pharmaceutical Industries Ltd
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (%)
FIGURE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, 2019-2027 (USD MILLION)
FIGURE 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, 2019-2027 (USD MILLION)
FIGURE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, 2019-2027 (USD MILLION)
FIGURE 10. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 11. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 12. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 14. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, 2019-2027 (USD MILLION)
FIGURE 15. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 16. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 17. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 18. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 23. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 24. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 25. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 26. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 27. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 28. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 29. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 30. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 31. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 32. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 33. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 34. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 36. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 53. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 54. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY REGION, 2019-2027 (USD MILLION)
TABLE 10. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 14. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY REGION, 2019-2027 (USD MILLION)
TABLE 15. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 20. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2019-2027 (USD MILLION)
TABLE 21. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 22. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY STATE, 2019-2027 (USD MILLION)
TABLE 23. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 25. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 26. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 27. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 28. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 30. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2019-2027 (USD MILLION)
TABLE 31. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY STATE, 2019-2027 (USD MILLION)
TABLE 33. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 36. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 38. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 41. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 42. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 43. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 44. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 45. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 46. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 47. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 48. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 49. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 50. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 51. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 52. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 53. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 54. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 55. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 56. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 57. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 59. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 60. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 61. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 62. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 63. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 64. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 65. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 66. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 67. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 68. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 69. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 70. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: SCORES
TABLE 71. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: BUSINESS STRATEGY
TABLE 72. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: PRODUCT SATISFACTION
TABLE 73. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: RANKING
TABLE 74. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 75. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: MERGER & ACQUISITION
TABLE 76. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 77. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 78. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: INVESTMENT & FUNDING
TABLE 79. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 80. GLOBAL ATOPIC DERMATITIS DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Connectics Corporation
  • Eli Lilly and Company
  • Encore Dermatology, Inc
  • Fujisawa Healthcare
  • Galderma S.A.
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche AG
  • LEO Pharma A/S
  • Meda AB
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown

Loading
LOADING...